Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Bruker Daltonics and Isis in Biosensor Alliance

By HospiMedica staff writers
Posted on 09 Aug 2006
A new alliance between Bruker Daltonics (Billerica, MA, USA), a subsidiary of Bruker BioSciences, and Isis Pharmaceuticals (Carlsbad, CA, USA) has been announced for the manufacturing and distribution of a new Ibis T5000 biosensor system. More...
This universal biosensor system can simultaneously identify thousands of types of infectious organisms in a sample.

Under the terms of the agreement, Bruker Daltonics will be the exclusive worldwide manufacturer of the Ibis T5000 biosensor system, which incorporates Bruker Daltonics' microtof electrospray ionization (esi)-tof (time of flight), or ESI-TOF, mass spectrometer. Bruker Daltonics will also be responsible for order processing, system installations, and service in North America, Europe and the Middle East. In Europe and the Middle East, Bruker Daltonics will have exclusive rights to sell Ibis T5000 systems and Ibis infectious organism identification kits for various government applications, and will have non-exclusive rights to sell to all other customers. Outside of Bruker Daltonics' exclusive market, Isis may sell Ibis T5000s and its infectious organism identification kits.

The Ibis T5000 utilizes the triangulation identification for the genetic evaluation of risks (TIGER) methodology, which is a combination of genomics, mathematical modeling, mass spectrometry, and molecular amplification to generate a "fingerprint” of each bacterium or virus, allowing it to identify virtually any bacteria or virus present in a sample. The Ibis T5000 biosensor system can rapidly identify or classify organisms that are newly-emerging, genetically altered, or unable to be cultured. The Ibis T5000 biosensor works with many different types of infectious samples from human samples, such as throat swabs or sputum, and environmental samples, such as soil or air.

Ibis plans to commercialize the Ibis T5000 biosensor system and associated reagents to government customers for use in biowarfare defense, epidemiologic surveillance, and forensics; and to non-government customers for use in pharmaceutical process control, hospital-associated infection control, and infectious disease diagnostics. The Ibis T5000 is currently designated for research use only (RUO) and has not yet been approved for any regulated uses, including in vitro diagnostics.

Bruker Daltonics develops innovative life science tools based on mass spectrometry, and also offers a broad line of nuclear, biologic and chemical detection products for homeland security.



Related Links:
Bruker Daltonics
Isis Pharmaceuticals

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.